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Background: HIV-1 Vif is essential for virus replication in natural target cells such as T cells and macrophages. Vif
recruits a ubiquitin ligase to degrade restrictive APOBEC3 proteins. APOBEC3G is one of the most potent retroviral
restriction factors targeted by Vif and, as such, the Vif-APOBEC3G interaction has emerged as a promising HIV-1
therapeutic target.
Methods: 20,000 small molecules were used in live-cell screens for those that preserve EGFP-APOBEC3G
fluorescence and luciferase-APOBEC3G luminescence in the presence of HIV-1 Vif.
Results: 2 compounds with similar core structures preserved APOBEC3G levels in the presence of Vif. 10 μM of
compound restored APOBEC3G to levels sufficient for incorporation into vif-proficient virus particles and restriction
of virus infectivity. Vif-dependent APOBEC3G polyubiquitination and general proteasomal activity were unaffected
at the same concentration.
Conclusions: The small molecules described here preserve APOBEC3G levels and activity in the presence of Vif.
These molecules are starting points for further development as antiretrovirals.
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Anti-retroviral therapies for patients with HIV-1 infection
have been greatly improved. Current therapies comprised
of combinations of three or more drugs can suppress viral
loads below detection threshold of clinical tests for many
years [1,2]. These therapies must be taken continuously
for the entire life of the patient because they do not elim-
inate integrated proviruses. This regimen unfortunately
can result in a variety of adverse long-term side effects
including renal dysfunction, osteoporosis, and cardio-
vascular diseases [2,3]. All approved drugs for HIV-1
infection, except CCR5 antagonists, are designed to target
viral enzymes, reverse transcriptase, protease and inte-
grase, and drugs that target accessory proteins have yet to
be developed for clinical use [2].
HIV-1 Vif is essential for viral replication in T cells and
macrophages [4,5]. Vif protects HIV-1 from restriction by* Correspondence: shind009@kuhp.kyoto-u.ac.jp
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unless otherwise stated.cellular APOBEC3 proteins [6-8]. Vif forms a ubiquitin
ligase complex with core-binding factor beta, cullin 5,
RING-box protein 2, elongin B, and elongin C, which
binds APOBEC3 proteins and promotes their poly-
ubiquitination and proteasomal degradation [9-13]. In the
absence of Vif protein, APOBEC3 can be incorporated
into budding virions and mutate viral genome during the
process of reverse transcription in target cells (reviewed in
[14]). APOBEC3 proteins are a family of DNA cytosine
deaminases which converts cytosines to uracils in single-
strand DNA [15-17]. Of these, APOBEC3D, APOBEC3F,
APOBEC3G, and APOBEC3H are capable of restricting
HIV-1 in T cells [18]. Over-expression of APOBEC3G
alone is sufficient for suppressing virus replication in T
cell-based spreading infection experiments [18]. Thus,
Vif-APOBEC3G interaction has been recognized as a
novel therapeutic target for patients with HIV-1 infection
[19]. The disruption of any of the steps required for Vif
function is expected to recover cellular APOBEC3G levels
and enable virus restriction. This concept was shown
originally by identifying a small compound using aLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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[20]. To further validate this concept and identify add-
itional candidate Vif-inhibitors, we have screened a library
of 20,000 small compounds for recovering APOBEC3G
expression levels in the presence of Vif, using EGFP- and
luciferase-based APOBEC3G expression systems. Here we
report two new molecules that elevate APOBEC3G levels
in the presence of Vif. Low concentrations of these com-
pounds result in a suppression of HIV-1 infectivity in the
presence of both APOBEC3G and Vif.
Results
Two small molecules which recover APOBEC3G
expression in the presence of HIV-1 Vif were identified by
a multi-round screening
To screen for small molecules that recover APOBEC3G
expression in the presence of HIV-1 Vif, we established
a high-throughput assay using EGFP-fused APOBEC3G.Figure 1 Two candidate molecules for inhibiting Vif-mediated degrad
A. Schematic depicting of the primary screening for Vif inhibitors using EG
the candidate small molecules. C. Structures of two candidate molecules sh
immunoblot analyses (panels) of the effect of two candidate molecules on
293 T cells transiently expressing EGFP-APOBEC3G in the presence of trans
24 hours. Fluorescence intensity was measured and that of DMSO-treated c
standard error of three independent experiments are shown in the histogr293 T cells were co-transfected with EGFP-fused APO-
BEC3G (EGFP-APOBEC3G) and a Vif expression vector
or an empty vector as a control. As described in many
prior reports, co-expression of Vif impairs APOBEC3G
expression, which can be quantified using a fluorescence
plate reader. If a small compound reduces the capacity
of Vif to downregulate EGFP-APOBEC3G, higher fluor-
escence intensity will be detected (Figure 1A). We used
this assay to screen a small compound library, and found
37 out of 20,000 compounds repeatedly recover fluores-
cence intensity more than 50%.
In the process of this screening, we noticed that if a com-
pound itself has fluorescence, it gives a false positive result
in the assay. To exclude such molecules, we performed a
secondary round of screening using a luciferase-fused
APOBEC3G (Luc-APOBEC3G). Similar to the primary
screen, 293 T cells were co-transfected with Luc-
APOBEC3G and the Vif expression vector or the emptyation of APOBEC3G were identified by a multi-round screening.
FP-fused APOBEC3G. B. Spreading infection of HIV-1 in the presence of
are similar backbone. D. Fluorescence measurement (histogram) and
EGFP-fused APOBEC3G protein levels in the presence of Vif protein.
ient expression of Vif were treated with 10 μM MM-1 or MM-2 for
ells without Vif expression was normalized to 100%. Average and
am.
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tified by enzyme-based chemiluminescence assays in the
presence of candidate small molecules. We found that ten
out of 37 compounds recovered luminescence intensity
more than 50%.
To determine whether any of these candidate molecules
actually inhibit the viral replication, we then performed
spreading infection experiments with these small mole-
cules using non-permissive CEM cells, which express
APOBEC3G sufficient to restrict vif-deficient HIV-1, and
permissive CEM-SS cells, which express less APOBEC3G.
We found that two out of ten small molecules appeared
to inhibit the viral replication in CEM cells, but not in
CEM-SS cells (Figure 1B), and called these molecules
MM-1 and MM-2. Interestingly, these two compounds
share similar backbone (Figure 1C). To confirm the effects
of MM-1 and MM-2 on APOBEC3G expression in the
presence of HIV-1 Vif, we performed immunoblotting
analyses for APOBEC3G as well as measuring the fluores-
cence intensity. 293 T cells were transfected with the ex-
pression vector for EGFP-APOBEC3G in the absence or
presence of co-transfection of the expression vector for
Vif, and treated with 10 μM of MM-1 or MM-2. Co-
transfection of Vif caused a reduction in fluorescence
intensity, and treatment with MM-1 or MM-2 caused
recovery of fluorescence intensity (Figure 1D, histogram),
consistent with our previous results of the primary screen-
ing. Of note, 100 μM MM-1 or MM-2, or 1% DMSO
alone does not cause fluorescence at detectable levels
(data not shown), suggesting the differences of fluores-
cence intensity we observed are not due to inherentFigure 2 Detailed analyses of the candidate molecules. A. Titration of the
intensity and protein levels of EGFP-fused APOBEC3G in a dose-dependent m
expression vectors and treated with different concentrations of MM-1 or MM-
without Vif expression was normalized to 100%. Cell lysates were also analyze
293 T cells were transfected with EGFP-APOBEC3G expression vector in the ab
with 10 μM MM-1 or MM-2 for 24 hours. Cells were analyzed similarly to A, av
in histogram.fluorescence of the small molecules. Consistent with fluor-
escence studies, immunoblotting analyses showed that
treatment with MM-1 or MM-2 significantly recovered
APOBEC3G protein levels (Figure 1D, panels).
The small compounds increased A3G expression in dose
dependent manners
We next performed a series of dose response experi-
ments. 293 T cells were transfected with the expression
vector for EGFP-APOBEC3G in the absence or presence
of co-transfection of the expression vector for Vif, and
treated with 5, 10, or 20 μM of MM1, or 2.5, 5, or 10 μM
of MM-2. The treatment of MM-1 or MM-2 caused re-
covery of fluorescence intensity in a dose-dependent man-
ner (Figure 2A, histogram). Consistent with these results,
APOBEC3G protein levels were also recovered by MM-1
or MM-2 treatment, while the levels of tubulin were com-
parable (Figure 2A, panels).
The effects of the small molecules on APOBEC3G levels
were greater in the presence of Vif
We next asked whether the effects of the small molecules
are dependent on APOBEC3G-Vif interaction. 293 T cells
were transfected with the expression vector for EGFP-
APOBEC3G, co-transfected with the expression vector for
Vif or an empty vector, and treated with MM-1 or MM-2,
or DMSO as control. In the fluorescence study, treatment
with MM-1 or MM-2 appeared to increase APOBEC3G
levels both in the absence and presence of Vif protein, but
the effects were greater in the presence of Vif protein than
those in the absence of Vif (Figure 2B, histogram, 2.3 foldtwo compounds. Treatment of MM-1 or MM2 recovered fluorescence
anner. 293 T cells were co-transfected with EGFP-APOBEC3G and Vif
2. Fluorescence intensity was measured and that of DMSO-treated cells
d by immunoblotting (panels). B. Vif dependency of the compounds.
sence or presence of co-transfection of Vif expression vector, and treated
erage and standard error of two independent experiments are shown
Figure 3 Candidate molecules impaired virus infectivity in the
presence of both APOBEC3G and Vif. VSV-G pseudo-typed
luciferase-reporter virus was produced in the presence or absence of
co-transfection of APOBEC3G expression vector. Before harvesting
virus-containing supernatant, 10 μM MM-1 or MM-2 were added to
culture medium. Harvested supernatant was challenged to fresh
293 T cells, and luciferase activity of lysates was measured after two
days. Samples of virus and producer cells were also analyzed by
immunoblotting. APOBEC3G levels in the virus particles were
recovered by treatment of the compounds.
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2). In the immunoblotting analyses, treatment with MM-1
or MM-2 dramatically recovered protein APOBEC3G
levels in the presence of Vif, but A3G levels were compar-
able in the absence of Vif (Figure 2B, panels). These
results suggest that the effects of these compounds are
mostly Vif-dependent, but we cannot exclude the possibil-
ity that these compounds are also effective in the absence
of Vif protein.
The small molecules increased APOBEC3G incorporation
into vif-proficient virus particles
We next asked whether the small molecules we found ac-
tually impair viral infectivity by using luciferase-reporter
virus. 293 T cells were transfected with NL4-3 ΔEnv-Luc
with co-transfection of a VSV-G expression vector, in the
co-transfection of an APOBEC3G expression vector, and
treated with MM-1 or MM-2, or DMSO as control. NL4-
3 ΔEnv ΔVif-Luc was also used for comparison. Superna-
tants were harvested and challenged to fresh 293 T cells.
The infectivity of vif-deficient virus was deeply impaired
by co-transfection of APOBEC3G, and the infectivities of
vif-proficient virus in the presence or absence of APO-
BEC3G were comparable as expected (Figure 3, histo-
gram). Treatment with MM-1 or MM-2 recovered
sensitivity of the virus to APOBEC3G (Figure 3, histo-
gram). Immunoblotting analyses showed recovery of
APOBEC3G levels in both producer cells and in virus par-
ticles by treatment of MM-1 or MM-2 (Figure 3, panels).
The small molecules did not inhibit ubiquitination of
APOBEC3G by HIV-1 Vif
To determine what step of the process the candidate
small molecules interfere, we first examined binding be-
tween APOBEC3G and Vif in the presence or absence of
the small molecules. 293 T cells were co-transfected with
expression vectors for Vif and carboxyl-terminally myc-
tagged APOBEC3G or empty vector, lysed with 0.1% tri-
ton X-100 containing buffer, and immunoprecipitated
with a monoclonal anti-myc antibody, with or without
addition of MM-1 or MM-2 in both cell culture and the
lysis buffer. MM-1 or MM-2 did not appear to inhibit
co-precipitation of Vif protein (Figure 4A), suggesting
that neither molecule inhibits binding between APO-
BEC3G and Vif. We next examined ubiquitination of
APOBEC3G by Vif in the presence or absence of the
small molecules. 293 T cells were transfected with the
expression vector for EGFP-APOBEC3G, with or without
co-transfection of the Vif expression vector, treated with
MM-1 or MM-2, or DMSO as control, immunoprecipi-
tated with anti-GFP antibody, then analyzed for ubiquitina-
tion of APOBEC3G by immunoblotting with anti-ubiquitin
antibody. Co-transfection of Vif resulted in several ubiqui-
tinated APOBEC3G with higher molecular weights, andtreatment with MM-1 or MM-2 appeared to make no dif-
ference in these bands (Figure 4B). These results suggest
that MM-1 or MM-2 does not inhibit Vif-mediated
ubiquitination of APOBEC3G, and are consistent with the
results of co-immunoprecipitation experiments. We next
examined whether the candidate small molecules inhibit
proteasomal activity by using an in vitro 20S proteasome
assay kit, which can measure chymotrypsin-like peptidase
activity of purified human erythrocyte 20S proteasome.
MM-1 or MM-2 was added in the reaction to test inhibi-
tory effects, DMSO was used as control for the small
molecules, and epoxomicin was used as a proteasome
inhibitor. Addition of MM-1 or MM-2 did not impair 20S
proteasome activities (Figure 4C), suggesting that recovery
of APOBEC3G by these compounds are not simply caused
by inhibiting the general proteasome activities.
Cytotoxicity studies of the compounds
We next examined cytotoxic effects of the candidate
small molecules. 293 T cells were incubated with various
concentrations of MM-1, MM-2 or DMSO for 48 hours,
and cell viability was then measured by MTS assays. We
Figure 4 The small molecules did not inhibit ubiquitination of
APOBEC3G or general proteasomal activity. A. 293 T cells were
transfected with the Vif expression vector, co-transfected with
APOBEC3G-myc expression vector or empty vector. 24 hours before
harvesting, MM-1, MM-2 or DMSO was added in culture media as
indicated. Cells were lysed and immunoprecipitated by anti-myc
antibody in the presence of the compound as indicated, and bound
protein was analyzed by immunoblotting with anti-Vif and anti-myc
sera. B. 293 T cells were transfected with expression vectors for
EGFP-fused APOBEC3G and HA-tagged ubiquitin, in the absence or
presence of co-transfection of the Vif expression vector, and treated
with MM-1, MM-2 or DMSO for 24 hours. Cells were then lysed, and
immunoprecipitated with anti-GFP rabbit serum. Bound protein was
analyzed by immunoblotting with anti-ubiquitin and anti-GFP
antibodies. C. An in vitro proteasome 20S assay kit was used for
testing inhibitory potential of the compounds to proteasomal
activity. DMSO was used as control for the compounds and
epoxomicin was used as control for proteasome inhibitor.
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10 μM or higher concentrations, and IC50 of MM-1 was
about 30 μM and that of MM-2 was about 50 μM
(Figure 5).
Discussion
We have used multi-round of screening based on APO-
BEC3G reporter systems and identified two candidate
small molecules for inhibiting Vif-mediated degradation
of APOBEC3G. We confirmed that the small molecules
recover APOBEC3G levels in producer cells by immuno-
blotting analyses as well as fluorescence measurement,
and also confirmed that these molecules recover incorpor-
ation of APOBEC3G into vif-proficient viruses. Our data
support the idea that inhibition of Vif-mediated degrad-
ation of APOBEC3G by small molecules can suppress
HIV-1 replication.
Nathans et al. reported 25 candidate small molecules
which recover APOBEC3G expression levels in the pres-
ence of Vif by using YFP- and RFP-fused APOBEC3G
protein [20]. However, none of these molecules have
structural similarity to the molecules we found, likely
because different libraries and/or different screening
methods were used. Our study therefore provides another
class of candidate Vif inhibitor compounds for further
development.
In the immunoprecipitation analyses, we did not
observe any change in ubiquitination of APOBEC3G by
treatment of MM-1 or MM-2, nor did we observe any
changes in co-immunoprecipitation experiments. These
results suggest that the small molecules do not interfere
with the Vif-APOBEC3G interaction. Moreover, the
compounds did not inhibit general proteasomal activity.
Therefore, the small molecules we identified might work
in the step between ubiquitination of APOBEC3G by Vif
and proteasomal degradation of ubiquitinated APO-
BEC3G. Considering that the molecules we identified
appeared to up-regulate APOBEC3G levels in cells even
in the absence of Vif protein, the molecules might bind
to APOBEC3G and make it more stable even after
ubiquitination. Because we used a cell-based screen that
relies upon fluorescence of EGFP-fused APOBEC3G,
candidate molecules may inhibit any step of the entire
process by which APOBEC3G is degraded. Additional
screens will be necessary to identify small molecules that
directly block the Vif-APOBEC3G interaction.
Of the two molecules we identified, MM-2 was more ef-
fective for causing a recovery in APOBEC3G levels as well
as the restriction of HIV-1, and it appeared to be less toxic
to 293 T cells. However, because cytotoxicity of the small
molecules we identified is observed at concentrations very
close to the concentration which these molecules are
effective, the molecules are not likely to become drugs for
patients with HIV-1 infection. However, considering the
Figure 5 Cytotoxicity of the small compounds. 293 T cells were treated with MM-1 or MM2 at indicated concentrations for 48 hours. Cell
viability was measured by MTS assay and normalized to that of DMSO-treated cells. Average and standard error of six independent experiments
are shown.
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backbone, derivatives with similar core structures might
become candidates for further development.
Conclusions
We have validated the concept that inhibiting Vif-mediated
degradation of APOBEC3G can result in restricted HIV-1
replication. In addition, we have added another structural
class to the growing library of candidate Vif-inhibiting small
molecules. Derivatives of the small molecules we identified
might become candidates for further development.
Methods
Plasmids
The expression vectors for EGFP-fused APOBEC3G and
Vif were previously described [21,22]. The expression
vector for HA-tagged APOBEC3G (pcDNA3/HA-A3G)
was previously described [23]. The expression vector for
luciferase-fused APOBEC3G was generated by inserting
coding sequence of luciferase gene amplified with
primers NNN NGC TAG CGC CAC CAT GGA AGA
CGC CAA AAA CAT and NNN NCT CGA GCA CGG
CGA TCT TTC CGC CCT at Nhe I and Xho I sites of
pcDNA3/HA-A3G. pNL4-3/ΔEnv-Luc and pNL4-3/
ΔenvΔVif-Luc vectors were previously described [21].
Cell culture and transfection
293 T cells were maintained in DMEM (Nacalai) con-
taining 10% FBS and 1% penicillin–streptomycin and
glutamine (PSG, Invitrogen). CEM and CEM-SS cells
were maintained in RPMI1640 containing 10% FBS and
1% PSG. 293 T cells on 6-well plates were transfected with
about 1 μg of plasmid DNA in total using X-tremegene
HP DNA transfection reagent (Roche) according to manu-
facturer’s instruction.Screening for small molecules that inhibit Vif-mediated
degradation of APOBEC3G
A library of small compounds was purchased from En-
amine. For the primary screening, 293 T cells on 24-well
plates were transfected with expression vectors for EGFP-
APOBEC3G and Vif and treated with individual molecules
from a library of small compounds for 24 hours, then cells
were lysed with M-PER (Pierce), and fluorescence inten-
sity was measured by plate reader (2030 Arvo X, Perkin
Elmer). DMSO was used for control for the compounds
and cells transfected with only EGFP-APOBEC3G were
used for positive control for fluorescence intensity. Experi-
ments were performed in duplicate and repeated once
more, and the compounds repeatedly recovered fluores-
cence intensity to more than 50% were selected to second-
ary screening. For the secondary screening, 293 T cells on
24-well plates were transfected with expression vectors for
Luc-APOBEC3G and Vif and treated with compounds for
24 hours, Passive lysis buffer (Promega) and luciferase
activity was determined by luminometer (2030 Arvo X,
Perkin Elmer) using Luciferase Assay System (Promega).
DMSO was used for control for the compounds and cells
transfected with only Luc-APOBEC3G were used for posi-
tive control. Experiments were performed in duplicate
and the compounds which recovered chemiluminescence
intensity to more than 50% were selected for tertiary
screening. For the tertiary screening, CEM and CEM-SS
cells were challenged with NL4-3 at 0.01 MOI and treated
with the compounds for 10 days. The compounds which
rescued virus-inducing cell death of CEM cells, but not
that of CEM-SS cells were selected.
Immunoblotting
Cells were lysed with triton-based buffer (20 mM
HEPES-HCl pH7.4, 150 mM NaCl, 1 mM EDTA, 0.1%
Matsui et al. Virology Journal 2014, 11:122 Page 7 of 8
http://www.virologyj.com/content/11/1/122triton X-100) supplemented with protease inhibitor
cocktail (Nacalai). After centrifugation at 20, 000 × g for
10 minutes, supernatant was mixed with sample buffer
(Biorad), boiled for 5 minutes, resolved on 10% (w/v)
polyacrylamide gel and transferred to PVDF membrane
(Immobilon, Millipore). The membrane was blocked for
non-specific binding of antibodies with 5% BSA containing
buffer for 1 hour and analyzed by standard immunoblot-
ting procedure. Primary antibodies for immunoblotting
against Vif, A3G and p24Gag were obtained from the NIH
AIDS Research and Reference Reagent Program. Mouse
anti-tubulin antibody was purchased from Covance. Rabbit
anti-GFP serum was purchased from Invitrogen. Mouse
anti-ubiquitin monoclonal antibody was purchased form
Santa Cruz. HRP-conjugated secondary antibodies against
mouse and rabbit were purchased from GE Healthcare.
Infectivity studies
Luciferase encoding HIV-1 particles were produced by
transiently transfecting 293 T cells at 50% confluency
using 0.6 μg pNL43/ΔEnv-Luc or pNL43/ΔEnvΔVif-Luc,
0.15 μg pVSV-G and 0.25 μg pcDNA3/HA-A3G, or an
empty vector. After 48 hours, virus-containing superna-
tants were harvested through PVDF filter with 0.45 μm
pores (Millipore), and challenged to fresh 293 T cells.
Medium were changed after 12 hours, cells were incubated
for additional 36 hours, lysed with Passive lysis buffer
(Promega) and luciferase activity was determined by
luminometer (2030 Arvo X, Perkin Elmer) using Luciferase
Assay System (Promega). Sample preparation of producer
cells and virus for immunoblotting was performed as
described [24].
Immunoprecipitation
For co-immunoprecipitation, 293 T cells were transfected
with the expression vectors for Vif, with co-transfection of
the expression vector for APOBEC3G-myc or empty vec-
tor. Cells were treated with 10 μM of MM-1, MM-2 or
DMSO only for 24 hours and 2.5 μMMG132 for 16 hours,
then washed with PBS, lysed with co-IP buffer (25 mM
HEPES, pH 7.4, 150 mM NaCl, 0.1% triton X-100, 1 mM
EDTA, 1 mM MgCl2, and 10% glycerol) supplemented
with protease inhibitor cocktail and 10 μM MG132,
centrifuged for 10 minutes at 20,000 × g. Supernatant was
incubated with anti-myc mouse monoclonal antibody
(clone 9E11) for 1 hour, and then mixed with 20 μl protein
A sepharose (Pharmacia) for 1 hour. Beads were washed
with co-IP buffer three times, and bound protein was
eluted with 1 × SDS sample buffer.
For testing ubiquitination of APOBEC3G, 293 T cells
were transfected with expression vectors for HA-tagged
ubiquitin and EGFP-fused APOBEC3G, with or without
co-transfection of the expression vector for Vif. Cells
were treated with 2.5 μM MG132 for 16 hours beforeharvest, then washed with PBS, lysed with RIPA buffer
(25 mM HEPES, pH 7.4, 150 mM NaCl, 0.1% SDS, 0.1%
sodium deoxycholate, 1% triton X-100, 1 mM EDTA) sup-
plemented with protease inhibitor cocktail and 10 μM
MG132, centrifuged for 10 minutes at 20,000 × g.
Supernatant was incubated with anti-GFP rabbit serum
(Invitrogen) for 1 hour, and then mixed with 20 μl protein
A sepharose (Pharmacia) for 1 hour. Beads were washed
with RIPA buffer three times, and bound protein was
eluted with 1 × SDS sample buffer. Samples were analyzed
by immunoblotting as described above.
Proteasomal activity studies
Proteasome 20S assay kit (Enzo) was used according to
manufacturer’s instruction. 10 μM of MM-1 or MM-2
was added to the reaction, and DMSO and epoxomicin
are used as controls.
Cytotoxicity studies
293 T cells were incubated with various concentration of
MM-1 or MM-2 for 48 hours, and cell viability was
measured by MTS assays using a kit (Promega). Cell via-
bility was normalized to that of cells incubated with the
same concentration of DMSO.
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